RVTY

Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 2026 8:00 a.m. GMT – Prahlad Singh, president and chief executive officer 9th Annual Evercore Healthcare Conference Wednesday, December 2, 2026 9:10 a.m. ET – Prahlad Singh Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days. About Revvity At

William Blair initiated coverage of Revvity with a rating of Outperform

Revvity, Inc. (NYSE:RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.Presentations from members of Revvity’s senior management team will provide updates on the Company’s key business initiatives, operational achievements and financial outlook.To register for the Investor Day webcast, visit here. A replay of the webcast and all presentations will be available on the Events page of the Revvity Investor Relations website following the event.About RevvityAt Revvity, "impossible" is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows fr

4 - REVVITY, INC. (0000031791) (Issuer)

Revvity, Inc. (NYSE:RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete work

Fully automated, multiplex autoantibody detection solution, enabling population-wide screening programs DBS-based newborn screening platform enables simple and scalable sample collection Expands Revvity’s diagnostic offerings from newborn into early childhood screening Revvity, Inc. (NYSE:RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear. A critical public health challenge, T1D is often only identified after significant beta-cell damage has occurred, p

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

UBS resumed coverage of Revvity with a rating of Neutral and set a new price target of $140.00

Acquisition strengthens Revvity’s position in human-relevant life sciences tools for next-generation GLP-1 and GPCR-targeting therapies for metabolic drug discovery Combines HCD’s human pancreatic beta cell models with Revvity’s capabilities in cell analysis, detection, high-content screening and gene editing Expands Revvity’s ability to support customers across the research-to-clinic continuum, including emerging applications in clinical development and regenerative medicine Revvity, Inc. (NYSE:RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical

RBC Capital Mkts initiated coverage of Revvity with a rating of Sector Perform and set a new price target of $135.00

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

4 - REVVITY, INC. (0000031791) (Issuer)

10-Q - REVVITY, INC. (0000031791) (Filer)

8-K - REVVITY, INC. (0000031791) (Filer)

Revenue of $730 million; pro forma revenue of $711 million; 4% pro forma revenue growth; 3% pro forma organic revenue growth GAAP EPS from continuing operations of $0.48; adjusted EPS from continuing operations of $1.41; GAAP pro forma EPS from continuing operations of $0.52; pro forma adjusted EPS from continuing operations of $1.41 Enters into definitive agreement to divest China Immunodiagnostics business Raises full year guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue f

The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, scr

4 - REVVITY, INC. (0000031791) (Issuer)

Revvity, Inc. (NYSE:RVTY) today published its 2026 Impact Report, highlighting the Company’s sustainability, social and governance strategy, initiatives and performance. The annual report showcases how the Company continues to translate innovation into real-world impact, while embedding responsible and sustainable practices through its operations. "At Revvity, we believe scientific innovation and responsible business practices go hand in hand," said Prahlad Singh, president and chief executive officer at Revvity. "We are proud of the progress we've made advancing our environmental, social and governance priorities, from strengthening transparency and environmental stewardship to expanding

Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workfl

New MCP connector extends Signals AI beyond the Signals One platform, enabling scientists to interact with connected R&D knowledge through Claude Claude accesses scientific data and organizational knowledge through Signals' intelligence layer, improving context-aware analysis and decision-making Collaboration combines industry-leading AI capabilities with trusted scientific workflows to help accelerate research and development Revvity, Inc. (NYSE:RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude, inc

Bernstein resumed coverage of Revvity with a rating of Mkt Perform and set a new price target of $115.00

11-K - REVVITY, INC. (0000031791) (Filer)

Scientists can now search, understand and act on complex R&D data in natural language by leveraging leading LLM capabilities within the Signals One platform Governed data and ontology-driven scientific context support reliable, traceable results across workflows Native agentic framework turns connected data and knowledge into task-ready insights for scientists Revvity, Inc. (NYSE:RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One™ platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions